CTLA4 and melanoma: Twyman-Saint Victor et al. [21] demonstrated that radiotherapy, in combination with inhibitors of cytotoxic T lymphocyte-associated antigen (CTLA4) and PD-L1, enhanced immunity through distinct mechanisms and increased abscopal response rates in melanoma.